Depressive symptom trajectories and polygenic risk scores in individuals with an immune-mediated inflammatory disease

[1]  Mi-Young Kim,et al.  Trajectories of Depressive Symptoms and Anxiety during Pregnancy and Associations with Pregnancy Stress , 2021, International journal of environmental research and public health.

[2]  R. Marrie,et al.  Mendelian randomization provides no evidence for a causal role in the bidirectional relationship between depression and multiple sclerosis , 2021, Multiple sclerosis.

[3]  Zina-Mary Manjaly,et al.  Major depressive disorder subtypes and depression symptoms in multiple sclerosis: What is different compared to the general population? , 2021, Journal of psychosomatic research.

[4]  D. Aarsland,et al.  Trajectories of depressive symptoms and associated patterns of cognitive decline , 2020, Scientific Reports.

[5]  V. Moreno,et al.  Identifying environmental risk factors for inflammatory bowel diseases: a Mendelian randomization study , 2020, Scientific Reports.

[6]  L. Lix,et al.  Validity and Reliability of Screening Measures for Depression and Anxiety Disorders in Rheumatoid Arthritis , 2020, Arthritis care & research.

[7]  C. Nemeroff,et al.  The Bidirectional Relationship of Depression and Inflammation: Double Trouble , 2020, Neuron.

[8]  E. Vassos,et al.  Polygenic risk scores: from research tools to clinical instruments , 2020, Genome Medicine.

[9]  E. Binder,et al.  Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms , 2020, JAMA psychiatry.

[10]  Kohske Takahashi,et al.  Welcome to the Tidyverse , 2019, J. Open Source Softw..

[11]  E. Derks,et al.  Genetic heterogeneity in self-reported depressive symptoms identified through genetic analyses of the PHQ-9 , 2019, Psychological Medicine.

[12]  S. Bae,et al.  Causal association between body mass index and risk of rheumatoid arthritis: A Mendelian randomization study , 2019, European journal of clinical investigation.

[13]  D. Geschwind,et al.  Defining the Genetic, Genomic, Cellular, and Diagnostic Architectures of Psychiatric Disorders , 2019, Cell.

[14]  J. Sareen,et al.  Comorbid anxiety, depression, and cognition in MS and other immune-mediated disorders , 2019, Neurology.

[15]  Anna Murray,et al.  Using genetics to understand the causal influence of higher BMI on depression , 2018, International journal of epidemiology.

[16]  Haniye Sadat Sajadi,et al.  Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2018, The Lancet.

[17]  R. Marioni,et al.  Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions , 2018, Nature Neuroscience.

[18]  L. Lix,et al.  The Validity and Reliability of Screening Measures for Depression and Anxiety Disorders in Inflammatory Bowel Disease. , 2018, Inflammatory bowel diseases.

[19]  L. Lix,et al.  Psychiatric comorbidity increases mortality in immune-mediated inflammatory diseases. , 2018, General hospital psychiatry.

[20]  Mary E. Haas,et al.  Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations , 2018, Nature Genetics.

[21]  S. Patten,et al.  Psychiatric comorbidity is associated with disability progression in multiple sclerosis , 2018, Neurology.

[22]  P. Visscher,et al.  Meta-analysis of genome-wide association studies for height and body mass index in ∼700,000 individuals of European ancestry , 2018, bioRxiv.

[23]  L. Lix,et al.  The validity and reliability of screening measures for depression and anxiety disorders in multiple sclerosis. , 2018, Multiple sclerosis and related disorders.

[24]  L. Lix,et al.  Effects of Psychiatric Comorbidity in Immune-Mediated Inflammatory Disease: Protocol for a Prospective Study , 2018, JMIR research protocols.

[25]  Alan M. Kwong,et al.  Next-generation genotype imputation service and methods , 2016, Nature Genetics.

[26]  Sheila B. Frankfurt,et al.  Using Group-Based Trajectory and Growth Mixture Modeling to Identify Classes of Change Trajectories , 2016 .

[27]  Jonathan P. Beauchamp,et al.  Genetic variants associated with subjective well-being, depressive symptoms and neuroticism identified through genome-wide analyses , 2016, Nature Genetics.

[28]  P. Zandi,et al.  Heterogeneity in long-term trajectories of depressive symptoms: Patterns, predictors and outcomes. , 2016, Journal of affective disorders.

[29]  C. Wilke.  Streamlined Plot Theme and Plot Annotations for 'ggplot2' , 2015 .

[30]  Gabor T. Marth,et al.  A global reference for human genetic variation , 2015, Nature.

[31]  Kosuke Imai,et al.  mediation: R Package for Causal Mediation Analysis , 2014 .

[32]  Terry L. Blackwell,et al.  Test Review: Patient Health Questionnaire–9 (PHQ-9) , 2014 .

[33]  R. Moos,et al.  Life stressors and resources and the 23-year course of depression. , 2013, Journal of affective disorders.

[34]  Kelsey Hegarty,et al.  A trajectory-based approach to understand the factors associated with persistent depressive symptoms in primary care. , 2013, Journal of affective disorders.

[35]  P. Lewinsohn,et al.  Heterogeneous trajectories of depressive symptoms: adolescent predictors and adult outcomes. , 2013, Journal of affective disorders.

[36]  A. Malla,et al.  The pattern of depressive symptoms in people with type 2 diabetes: a prospective community study. , 2013, Journal of psychosomatic research.

[37]  H. Hsu.  Group‐based trajectories of depressive symptoms and the predictors in the older population , 2012, International journal of geriatric psychiatry.

[38]  R. Cross,et al.  Psychosocial factors contributing to inflammatory bowel disease activity and health-related quality of life. , 2012, Gastroenterology & hepatology.

[39]  W. Ye,et al.  Multiple trajectories of depressive symptoms in middle and late life: racial/ethnic variations. , 2011, Psychology and aging.

[40]  C. Bernstein,et al.  Psychiatric Disorders in Patients with Immune-Mediated Inflammatory Diseases: Prevalence, Association with Disease Activity, and Overall Patient Well-being , 2011, The Journal of Rheumatology. Supplement.

[41]  N. Wray,et al.  Genetic risk profiles for depression and anxiety in adult and elderly cohorts , 2010, Molecular Psychiatry.

[42]  David Kessler,et al.  Concordance between PHQ-9 scores and patients' experiences of depression: a mixed methods study. , 2010, The British journal of general practice : the journal of the Royal College of General Practitioners.

[43]  D. Takeuchi,et al.  Variation in the Trajectories of Depressive Symptoms: Results from the Americans' Changing Lives Study , 2010, Biodemography and social biology.

[44]  Theo Stijnen,et al.  Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. , 2010, Archives of general psychiatry.

[45]  K. Salmela‐Aro,et al.  Trajectories of depressive symptoms during emerging adulthood: Antecedents and consequences , 2008 .

[46]  J. Swendsen,et al.  Risk and protective factors associated with trajectories of depressed mood from adolescence to early adulthood. , 2008, Journal of consulting and clinical psychology.

[47]  Michael E. Ezell,et al.  Identifying Trajectories of Depressive Symptoms for Women Caring for Their Husbands with Dementia , 2008, Journal of the American Geriatrics Society.

[48]  Daniel S. Nagin,et al.  Advances in Group-Based Trajectory Modeling and an SAS Procedure for Estimating Them , 2007 .

[49]  D. Reich,et al.  Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.

[50]  M. Stoolmiller,et al.  The course of depressive symptoms in men from early adolescence to young adulthood: identifying latent trajectories and early predictors. , 2005, Journal of abnormal psychology.

[51]  P. Rutgeerts,et al.  The impact of major depressive disorder on the short‐ and long‐term outcome of Crohn's disease treatment with infliximab , 2005, Alimentary pharmacology & therapeutics.

[52]  B. Löwe,et al.  Measuring depression outcome with a brief self-report instrument: sensitivity to change of the Patient Health Questionnaire (PHQ-9). , 2004, Journal of affective disorders.

[53]  P. McLeod,et al.  The Relation of Body Mass Index to Depressive Symptoms , 2004, Canadian Journal of Public Health.

[54]  C. Mittermaier,et al.  Impact of Depressive Mood on Relapse in Patients With Inflammatory Bowel Disease: A Prospective 18-Month Follow-Up Study , 2004, Psychosomatic medicine.

[55]  R. Spitzer,et al.  The PHQ-9 , 2001, Journal of General Internal Medicine.

[56]  P. Lewinsohn,et al.  Clinical implications of "subthreshold" depressive symptoms. , 2000, Journal of abnormal psychology.

[57]  R. Spitzer,et al.  Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. , 1999, JAMA.

[58]  N. Nagelkerke,et al.  A note on a general definition of the coefficient of determination , 1991 .

[59]  OUP accepted manuscript , 2021, Journal of Crohn’s and Colitis.

[60]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[61]  C. Anderson‐Cook,et al.  Group-Based Modeling of Development , 2006 .

[62]  R. Spitzer,et al.  The PHQ-9: validity of a brief depression severity measure. , 2001, Journal of general internal medicine.